Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.
作者信息
Hütter-Krönke Marie Luise, Fiedler Walter, Kündgen Andrea, Krauter Jürgen, von Lilienfeld-Toal Marie, Döhner Hartmut, Schlenk Richard F
机构信息
Department of Internal Medicine III, University of Ulm
Department of Internal Medicine II, University Hospital Hamburg-Eppendorf, Hamburg.
出版信息
Haematologica. 2019 Feb;104(2):e63-e64. doi: 10.3324/haematol.2018.199794. Epub 2018 Aug 31.
Abstract
摘要
相似文献
1
Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.在复发、难治或不适合其他治疗方案的老年新诊断急性髓系白血病患者中持续高剂量使用来那度胺——一项I期研究的结果
Haematologica. 2019 Feb;104(2):e63-e64. doi: 10.3324/haematol.2018.199794. Epub 2018 Aug 31.
2
Management of primary refractory acute myeloid leukemia in the era of targeted therapies.靶向治疗时代的原发性难治性急性髓系白血病的治疗。
Leuk Lymphoma. 2019 Mar;60(3):583-597. doi: 10.1080/10428194.2018.1504937. Epub 2018 Sep 20.
3
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.65 岁及以上新诊断为急性髓系白血病患者中连续高剂量来那度胺、序贯阿扎胞苷和来那度胺或阿扎胞苷的随机研究。
Haematologica. 2018 Jan;103(1):101-106. doi: 10.3324/haematol.2017.172353. Epub 2017 Nov 2.
4
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.伏瑞洛星在首次复发或难治性急性髓系白血病患者中的安全性和疗效——一项关键性评价。
Expert Rev Hematol. 2016 Jun;9(6):529-34. doi: 10.1080/17474086.2016.1187063. Epub 2016 May 24.
5
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.考洛菲兰、高剂量阿糖胞苷和脂质体柔红霉素治疗儿科复发/难治性急性髓系白血病的初步研究
Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17.
6
A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.一项关于卡非佐米用于复发或难治性急性髓系白血病和急性淋巴细胞白血病的I期研究。
Leuk Lymphoma. 2016;57(3):728-30. doi: 10.3109/10428194.2015.1076930. Epub 2015 Oct 5.
7
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.来那度胺联合地塞米松治疗复发或难治性慢性淋巴细胞白血病的安全性和有效性研究（LenD研究）
Leuk Lymphoma. 2018 Jul;59(7):1730-1733. doi: 10.1080/10428194.2017.1399311. Epub 2017 Nov 22.
8
Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.艾达司珠单抗作为改善复发/难治性急性髓系白血病治疗历程的一种新的治疗选择。
Future Oncol. 2020 May;16(14):887-889. doi: 10.2217/fon-2020-0218. Epub 2020 Apr 27.
9
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.来那度胺、沙利度胺和地塞米松联合治疗复发和/或难治性多发性骨髓瘤的I/II期试验。
Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4.
10
Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.复发或难治性急性髓系白血病成人患者早期死亡的预测
Leuk Lymphoma. 2016 Oct;57(10):2421-4. doi: 10.3109/10428194.2015.1135436. Epub 2016 Jan 11.
引用本文的文献
1
-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment Strategies.- 突变型急性髓系白血病：在新型治疗策略时代破解分子与临床谜题
Cancers (Basel). 2025 Jun 23;17(13):2095. doi: 10.3390/cancers17132095.
2
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.维奈克拉联合阿扎胞苷和供者淋巴细胞输注治疗异基因造血干细胞移植后复发的急性髓系白血病患者。
Ann Hematol. 2022 Jan;101(1):119-130. doi: 10.1007/s00277-021-04674-x. Epub 2021 Sep 27.
3
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.急性髓系白血病发展过程中白血病干细胞与骨髓微环境的相互作用
Exp Hematol Oncol. 2021 Jul 10;10(1):39. doi: 10.1186/s40164-021-00233-2.
4
Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look.急性髓系白血病与骨髓微环境——深入探究
Front Oncol. 2018 Oct 12;8:444. doi: 10.3389/fonc.2018.00444. eCollection 2018.
本文引用的文献
1
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.65 岁及以上新诊断为急性髓系白血病患者中连续高剂量来那度胺、序贯阿扎胞苷和来那度胺或阿扎胞苷的随机研究。
Haematologica. 2018 Jan;103(1):101-106. doi: 10.3324/haematol.2017.172353. Epub 2017 Nov 2.
2
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.低剂量来那度胺联合阿糖胞苷治疗极老年、身体状况不佳的急性髓系白血病患者：一项II期研究的最终结果
Leuk Res. 2017 Nov;62:77-83. doi: 10.1016/j.leukres.2017.09.019. Epub 2017 Sep 25.
3
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.一项针对复发/难治性高危骨髓增生异常综合征和具有三系发育异常的急性髓系白血病患者的大剂量来那度胺2期试验。
Br J Haematol. 2017 Jan;176(2):241-247. doi: 10.1111/bjh.14407. Epub 2016 Oct 28.
4
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.中剂量阿糖胞苷联合来那度胺治疗复发/难治性急性髓系白血病的I期研究
Leuk Res. 2016 Apr;43:44-8. doi: 10.1016/j.leukres.2016.02.003. Epub 2016 Feb 16.
5
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.来那度胺诱导del(5q)骨髓增生异常综合征中CK1α的泛素化和降解。
Nature. 2015 Jul 9;523(7559):183-188. doi: 10.1038/nature14610. Epub 2015 Jul 1.
6
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.一项高剂量来那度胺作为初治老年急性髓系白血病患者的 2 期研究。
Blood. 2011 Feb 10;117(6):1828-33. doi: 10.1182/blood-2010-07-297143. Epub 2010 Nov 4.
7
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.来那度胺治疗复发或难治性急性白血病的剂量递增。
J Clin Oncol. 2010 Nov 20;28(33):4919-25. doi: 10.1200/JCO.2010.30.3339. Epub 2010 Oct 18.
8
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.单药来那度胺可使孤立性13号染色体三体的急性髓系白血病患者完全缓解。
Blood. 2009 Jan 29;113(5):1002-5. doi: 10.1182/blood-2008-04-152678. Epub 2008 Sep 29.
9
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.来那度胺单药治疗JAK2（V617F）阳性、del（5）（q13q33）骨髓增生异常综合征所致急性髓系白血病的血液学和细胞遗传学反应
Leukemia. 2006 Nov;20(11):2063-4. doi: 10.1038/sj.leu.2404398. Epub 2006 Sep 21.
Zotero 插件